Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
How this was made

The 30-second read
Why it matters
Earnings miss may lead to short-term price declines; revenue growth suggests potential for future recovery.
Market read
The news is highly relevant for traders focusing on biotech stocks, especially CGEN, with potential short-term volatility.
What to watch
Broader market trends and upcoming catalysts could influence stock movement beyond earnings results.
Background
Compugen is a biotech company reporting Q1 2025 earnings, with notable revenue growth but significant earnings miss.
Ticker impact
The news directly pertains to Compugen's recent quarterly earnings report, making it highly relevant for short-term trading decisions.
Potential short-term decline followed by stabilization or slight rebound as investors digest the mixed results.
Earnings misses typically exert downward pressure, but strong revenue growth can mitigate negative sentiment. The net effect depends on investor perception and broader market conditions.
Market effects
Potential cautiousness in biotech and life sciences sectors due to earnings volatility.
Limited regional impact; primarily affects US-based biotech stocks.
Minimal; specific to US biotech sector.
Counterpoint
The revenue beat indicates underlying strength; the stock may rebound after initial sell-off.
Key entities
- CompanyCompugen Ltd.
Biotech firm focused on immuno-oncology and other therapeutic areas.




